Dearborn Partners’s Akebia Therapeutics AKBA Stock Holding History

Dearborn Partners’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-18,020	Closed	-$200K	–	214
2015 Q1	$200K	Buy	18,020 +3,700	+26%	+$39.4K	0.02%	283
2014 Q4	$167K	Buy	+14,320	New	+$205K	0.02%	285

Other funds holding AKBA

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Dearborn Partners's AKBA Position: Q2 2015 in Review

Dearborn Partners sold out of Akebia Therapeutics (AKBA) in Q2 2015, closing a stake of 18,020 shares — an estimated $200K sold.

Dearborn Partners first reported a position in AKBA in Q4 2014 and held it in 2 quarters. The position peaked at $200K in Q1 2015. 73 funds tracked by Wall St. Rank hold AKBA as of Q2 2015.

Dearborn Partners reported no remaining Akebia Therapeutics position as of Q2 2015 after selling out during the quarter.
Dearborn Partners sold 18,020 Akebia Therapeutics shares in Q2 2015, an estimated $200K.
Dearborn Partners first reported a position in Akebia Therapeutics in Q4 2014 and held it in 2 quarters.
Dearborn Partners's Akebia Therapeutics position peaked at $200K in Q1 2015.
73 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2015.

Based on Dearborn Partners's 13F filing for Q2 2015, filed 13 Aug 2015.